#pharmaceutical-industry

#pharmaceutical-industry

The desire to stop your own tragedies from happening to someone else may be a strong motivator. However, the process of drug discovery has always been grindingly, gruelingly slow.

Ireland's position is that the treatment of pharma should be within negotiations with the EU on an agreement in principle, a crucial sector for our economy.

Anticipating early client shifts, Gopalakrishnan Mahadevan strategically guided his team to onboard techno-functional SMEs with relevant experience, strengthening the company's position for project support.

Hikma's generic Vascepa, with its "skinny label," poses a challenge for patent protection, potentially undermining the incentives for innovation in the pharmaceutical industry.

In 2004-2005, new regulations mandated full disclosure of clinical trial data, allowing independent researchers to analyze statins' primary data, revealing exaggerated benefits.

One policy advocate described the move as "a total capitulation to the demands of drug corporation lobbyists."

Starmer emphasized that the new US tariffs present a considerable challenge, with their economic impact posing significant concerns for Britain's industrial and export sectors.

"Tariffs are bad but from an Irish perspective, if Trump goes on to focus on the pharmaceutical sector in Ireland, that will be the real nightmare scenario, in my view."

Police are actively investigating an arson case involving the North Jersey home of a Bayer executive, raising alarms about targeted violence against healthcare industry leaders.

Ireland has successfully attracted US pharmaceutical companies through favorable tax measures, resulting in a significant trade deficit for the US.

Medicare's recent selection of 15 medications for price negotiations represents a substantial focus on lowering costs, especially drugs critical for diabetes, obesity, and cancer treatment.

"Over the last five years, there has been a sharp rise in targeted attacks, digital and offline, of executives and their families... health care, biomedical and pharmaceutical leaders tend to be targeted more often than executives in other industries."